| scholarly article | Q13442814 |
| P2093 | author name string | B A C Dijkmans | |
| W F Lems | |||
| J W R Twisk | |||
| A E Voskuyl | |||
| M J L Peters | |||
| M T Nurmohamed | |||
| V P van Halm | |||
| R J van de Stadt | |||
| G J Wolbink | |||
| M H M T de Koning | |||
| M Vis | |||
| P2860 | cites work | The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 |
| Inflammation, atherosclerosis, and coronary artery disease | Q29547232 | ||
| Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group | Q29619877 | ||
| Longitudinal data analysis. A comparison between generalized estimating equations and random coefficient analysis | Q33207694 | ||
| Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis | Q34283776 | ||
| Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis | Q34315745 | ||
| Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? | Q34601733 | ||
| Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis | Q35547305 | ||
| Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis | Q35553035 | ||
| Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy | Q35640331 | ||
| Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis | Q43049221 | ||
| Dyslipoproteinemia in patients with active rheumatoid arthritis: effects of disease activity, sex, and menopausal status on lipid profiles. | Q43426783 | ||
| Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction | Q44063971 | ||
| Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. | Q44068950 | ||
| Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. | Q44123361 | ||
| Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment | Q44350203 | ||
| Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study | Q44973310 | ||
| Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation | Q45004490 | ||
| Effect of anti TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol | Q45110323 | ||
| Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis | Q45251969 | ||
| Lipid profiles among US elderly with untreated rheumatoid arthritis--the Third National Health and Nutrition Examination Survey. | Q46838483 | ||
| Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. | Q51631986 | ||
| Tumor necrosis factor-alpha production is associated with less body cell mass in women with rheumatoid arthritis. | Q54568998 | ||
| High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial | Q68915842 | ||
| Long-term effects of varying intensities and formats of physical activity on participation rates, fitness, and lipoproteins in men and women aged 50 to 65 years | Q72220332 | ||
| Cholesterol and coronary heart disease: predicting risks by levels and ratios | Q72764055 | ||
| Lipoprotein(a) and lipids in relation to inflammation in rheumatoid arthritis | Q74169414 | ||
| Lipid profiles in untreated patients with rheumatoid arthritis | Q78139431 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 958-961 | |
| P577 | publication date | 2007-02-21 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis | |
| P478 | volume | 66 |
| Q37728928 | A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis |
| Q42406811 | An overview of lipid abnormalities in patients with inflammatory bowel disease |
| Q34348277 | Anti-TNFα therapy transiently improves high density lipoprotein cholesterol levels and microvascular endothelial function in patients with rheumatoid arthritis: a pilot study. |
| Q48444714 | Anti-arthritogenic and cardioprotective action of hesperidin and daidzein in collagen-induced rheumatoid arthritis |
| Q51673816 | Are lipid ratios less susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis? |
| Q36238859 | Atherogenic index and high-density lipoprotein cholesterol as cardiovascular risk determinants in rheumatoid arthritis: the impact of therapy with biologicals |
| Q36596894 | Atherogenic lipid profiles and its management in patients with rheumatoid arthritis |
| Q38738136 | Atherosclerotic cardiovascular disease in patients with chronic inflammatory joint disorders |
| Q34563216 | Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment |
| Q49166358 | Circular RNA expression profiles of peripheral blood mononuclear cells in rheumatoid arthritis patients, based on microarray chip technology. |
| Q35029916 | Dyslipidaemia in rheumatological autoimmune diseases |
| Q36113215 | Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy |
| Q38323310 | Effects of TNFα inhibitors on adiposity and other cardiovascular risk factors: implications for the cardiovascular prognosis in patients with rheumatoid arthritis |
| Q37405950 | Effects of anti-TNF-α treatment on lipid profile in rheumatic diseases: an analytical cohort study. |
| Q46085890 | Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn's disease |
| Q60809264 | Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis |
| Q53653844 | Glucocorticoid use is associated with increase in HDL and no change in other lipids in rheumatoid arthritis patients. |
| Q38293477 | Impact of systemic inflammation and autoimmune diseases on apoA-I and HDL plasma levels and functions |
| Q48003836 | Impact of treatment with TNF antagonists on total cholesterol in patients with ankylosing spondylitis and psoriatic arthritis |
| Q38026796 | Lipid paradox in rheumatoid arthritis: changes with rheumatoid arthritis therapies |
| Q34684331 | Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease |
| Q46195508 | Lipid profile and anti-TNF-α use. |
| Q38181566 | Lipid profile changes in patients with rheumatic diseases receiving a treatment with TNF-α blockers: a meta-analysis of prospective studies |
| Q94585780 | Low-density lipoprotein cholesterol lowering treatment: the current approach |
| Q34162072 | Modifications in lipid levels are independent of serum TNF-α in rheumatoid arthritis: results of an observational 24-week cohort study comparing patients receiving etanercept plus methotrexate or methotrexate as monotherapy |
| Q36724093 | Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines |
| Q41466368 | Prevalence of dyslipidemia in Japanese patients with rheumatoid arthritis and effects of atorvastatin treatment |
| Q37540440 | Psoriasis comorbidities: complications and benefits of immunobiological treatment |
| Q37472928 | Role for TNF in atherosclerosis? Lessons from autoimmune disease |
| Q50318500 | Serum Lipid Alterations in Early Rheumatoid Arthritis Patients on Disease Modifying Anti Rheumatoid Therapy. |
| Q50109832 | The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review |
| Q37427394 | The effect of etanercept on traditional metabolic risk factors for cardiovascular disease in patients with rheumatoid arthritis |
| Q61454160 | The effects of conventional drugs in the treatment of rheumatoid arthritis on the serum lipids |
| Q37343272 | The impact of inflammation on metabolomic profiles in patients with arthritis |
| Q37778588 | Toxicity and Monitoring of Immunosuppressive Therapy Used in Systemic Autoimmune Diseases |
| Q36464352 | Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis |
| Q35295398 | Treatment of rheumatoid arthritis with marine and botanical oils: influence on serum lipids |
| Q37479238 | Use of lipid-lowering agents in rheumatoid arthritis: a population-based cohort study |
Search more.